Medtech Startups to Watch: Five Standout Innovators from LSI Asia ’26

Every LSI event brings together dozens of companies developing new medical technologies, but a handful always leave a particularly strong impression. Following LSI Asia ‘26 in Singapore, LSI’s Market Intelligence team reviewed presentations from more than 70 companies to identify five medtech startups that stood out based on their technology, commercial potential, recent milestones, and the markets they are pursuing.

One trend became immediately apparent. Many of this year’s most compelling innovators came from across the Asia-Pacific region, demonstrating that companies headquartered in Singapore, China, and Thailand are increasingly building technologies designed for global adoption rather than regional markets alone.

Below are five companies that captured our attention and the market dynamics supporting each opportunity.

Aqua Medical

Aqua Medical is developing an endoscopic treatment designed to address type 2 diabetes through a minimally invasive procedure instead of lifelong drug therapy.

Its RFVA platform enables PIMA (Proximal Intestinal Mucosal Ablation), an outpatient procedure that ablates 50 to 70 centimeters of the proximal intestine to restore metabolic signaling that drives type 2 diabetes. The approach requires no implants, no surgical incisions, and no ongoing medication.

Clinical progress has been encouraging. Aqua Medical has treated 66 patients, received FDA Breakthrough Device Designation, and secured FDA IDE approval in late 2025 for its U.S. type 2 diabetes pilot study. At Digestive Disease Week 2026, the company reported an average A1C reduction of approximately 2.1% while achieving complete insulin elimination after 12 months in a 20-patient cohort. Aqua Medical also holds FDA 510(k) clearance for Barrett’s esophagus, providing an established regulatory foundation as its diabetes program advances.

The opportunity is significant. Approximately 38 million Americans live with diabetes, with 90 to 95% diagnosed with type 2 disease, while the International Diabetes Federation estimates roughly 589 million adults worldwide are affected.

Rather than replacing GLP-1 therapies, Aqua Medical’s technology could complement them by offering a durable procedural option for patients who cannot tolerate, afford, or remain on long-term drug therapy.

2Strands Biosciences

Singapore-based 2Strands Biosciences is focused on making molecular residual disease monitoring more broadly accessible through its blood-based ctDNA test, Recura.

The company’s proprietary allele-enrichment sequencing approach is designed to detect variant allele frequencies as low as 0.001%, approaching the performance of leading institutional liquid biopsy platforms while targeting a substantially lower cost.

2Strands has completed the NUS Medicine accelerator, participated in MedTech Innovator Asia Pacific 2025, and closed a pre-seed financing led by Elev8 VC. The company plans to raise a Seed round during Q4 2026 as it advances Recura toward Laboratory Developed Test status in the United States.

The broader liquid biopsy market was valued at approximately $6 billion to $10 billion in 2024 and is projected to reach roughly $22 billion to $31 billion by the mid-2030s. Molecular residual disease monitoring represents the fastest-growing segment, with the U.S. MRD testing market estimated at about $874 million in 2024.

Because serial ctDNA testing has demonstrated the ability to detect recurrence months before conventional imaging, reducing testing costs could become an important driver of wider clinical adoption.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/medtech-startups-to-watch-five-standout-innovators-from-lsi-asia-26